SYNERGY™ & SYNERGY MEGATRON™

Everolimus-Eluting Platinum Chromium Coronary Stent System

The SYNERGY Bioabsorbable Polymer (BP) Stent was Designed to Provide Early Healing

The SYNERGY BP Stent works synergistically, emphasizing the suppression of neointimal growth at the arterial wall while promoting healing inside the vessel. It features the Synchrony™ Bioabsorbable Polymer Coating, which is applied only to the abluminal side of the stent to promote rapid endothelialization.1,2

Explore

Freedom from Long-Term Polymer Exposure

The polymer on the SYNERGY BP Stent is absorbed when it’s no longer needed, shortly after the drug is completely eluted at three months, providing early healing and freedom from long-term polymer exposure.1

It was designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis and late stent thrombosis.

Everolimus is still present in the tissue out to 120-days while polymer completes absorption

Synchronous Absorption1
Thinner stent struts also impact healing. Stents with thinner strut designs have been proven to heal faster than thicker strut stents.3 The SYNERGY BP Stent has ultra-thin 74 µm* struts, which have shown more rapid healing compared to thicker stent strut designs in clinical cases and in preclinical research.4,5
* Strut thickness for small vessel model is 0.0029” (74μm), Workhorse model is 0.0031” (79μm) and large vessel is 0.0032” (81μm). Boston Scientific data on file.
1. Wilson GJ et al, Catheter Cardiovasc Interv. 2015.
2. Eppihimer M, PhD. Impact of Polymer Type and Location on Stent Thrombogenicity and Endothelial Cell Coverage. EuroPCR 2014.
3. Soucy N, Feygin J et al, EuroIntervention. 2010 Nov;6(5):630-7.
4. Presented by J. M. de la Torre, MD at EuroPCR 2014.
5. Presentation by Kazuyuki Yahagi, MD; Michael Joner, MD; Renu Virmani, MD at TCT 2014.
6. Adapted from presentations by Juan Granada, MD at TCT 2014 (and PCR 2014). Evaluated the PtCr Bare-Metal Stent. Preclinical: Diseased Porcine Model.
 

Early Healing

High Bleeding Risk Indication

Lower Inflammation Rates3

In a preclinical model, SYNERGYTM BP Stent demonstrated:

  • Significantly reduced Early Inflammation versus Bare Metal Stents (BMS)
  • Significantly reduced Late Inflammation versus Permanent Polymer (PP) Stents
High Bleeding Risk Indication

Not All Bioabsorbable Polymer Stents are Created Equal

BP Stents differ in terms of polymer application, polymer type, polymer absorption time, drug type, drug elution times and stent design.
High Bleeding Risk Indication
 

Optimal Healing Shown Through Strut Coverage and Angioscopy

SYNERGY BP Stent has shown full stent strut coverage as early as 30-days in humans and showed 0% stent thrombosis in all of these OCT analyses.6
High Bleeding Risk Indication
1. Soucy N, Feygin J et al, EuroIntervention. 2010 Nov;6(5):630-7.
2. Wilson GJ, et al. Catheter Cardiovasc Interv.
3. Adapted from presentations by Juan Granada, MD at TCT 2014 (and PCR 2014). Evaluated the PtCr Bare-Metal Stent. Preclinical: Diseased Porcine Model.
4. Garg, S, J Am Coll Cardiol. 2010;56 (10s1):S43-S78. doi:10.1016.
5. Presented by Stephan Windecker, MD, TCT2012.
6. Adapted from presentation by Ida Riise Balleby, MD at ACC 2016.
7. Adapted from presentation by Juan Granada, MD, at CRT 2015.
8. Adapted from presentation by JM de la Torre, MD at PCR 2015.
9. Nakayoshi T, Ueno T, Sasaki K, et al. Differential angioscopic findings of neointimal coverage among first-, second-, and next generation drug eluting stents. Int J Cardiol. 2016;223:450-451. Images courtesy of Professor Ueno.
 
Clinical Program

Clinical Program

Addressing the full spectrum of cardiovascular disease complexity

Button
Real-World

Real-World Studies

How design impacts economic value

Button
Top